Learn what halicin is, how this AI-discovered antibiotic works, and why its novel mechanism and activity against multidrug-resistant bacteria make it a breakthrough in the fight against antimicrobial resistance.
Learn how AI-driven pharmacovigilance, NLP, and machine learning are transforming drug safety monitoring—from static case review to real-time safety intelligence across EHRs, regulatory databases, and real-world evidence.
Learn how GLP‑1/GIP dual agonists like tirzepatide work at the molecular level to enhance insulin secretion, improve glucose control, and drive greater weight loss than GLP‑1 drugs alone. Explore mechanisms, incretin hormones, and key clinical trial results.
Discover how Pharmacovigilance 3.0 is transforming drug safety from manual case review to an AI‑first, continuously learning ecosystem using large language models, multimodal analytics, and real‑time risk prediction to augment clinical judgment at scale.
Discover how generative AI is transforming small molecule drug discovery, from VAEs and GANs to reinforcement learning and diffusion models, enabling rapid design of novel drug-like compounds optimized for potency, selectivity, and developability.
Learn what zavegepant is, how this next-generation CGRP receptor antagonist works, and why its fast-acting nasal spray formulation is a game-changer for acute migraine treatment, especially for patients with nausea or vomiting.
Discover how AI and machine learning are revolutionizing pharmacovigilance—from intelligent case intake and triage to continuous, real‑time safety surveillance across EHRs, wearables, social media, and real‑world data to detect adverse drug reactions faster and improve drug safety.
Learn how tirzepatide works as a dual GIP and GLP‑1 receptor agonist, why it’s different from traditional GLP‑1 drugs, and what clinical trials like SURMOUNT‑1 and SURPASS show for weight loss and type 2 diabetes control.
Learn how targeted protein degraders, especially PROTACs, are transforming small molecule drug discovery by degrading disease‑driving proteins, expanding druggable targets beyond classical enzyme and receptor inhibition.
Learn what MRTX1133 is, how it selectively targets the KRAS G12D mutation, and why this first-in-class, non-covalent inhibitor is reshaping the landscape of precision oncology for pancreatic, colorectal, and lung cancers.